Pediatrix Medical Group

MD · NYSE

$28.08+$0.78 (+2.86%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $27.30

MD analyst rating

HoldConsensus of 3 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold3
Underperform0
Sell0

12-month price target · 9 analysts

Average $26.86 (−4.3% downside)

Low: $21.21
Now: $28.08
High: $29.40

Upgrades and downgrades

The latest rating actions, newest first

MD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Jefferies	Aug 19, 2026	Downgrade	Buy → Hold	$27.00 → $28.00	80%
UBS	Aug 6, 2026	Maintains	Neutral	$25.00 → $28.00	64%
Truist Securities	Jul 14, 2026	Maintains	Hold	$23.00 → $28.00	67%
UBS	May 12, 2026	Maintains	Neutral	$22.00 → $25.00	64%
Truist Securities	Apr 13, 2026	Maintains	Hold	$21.00 → $23.00	67%
UBS	Feb 24, 2026	Maintains	Neutral	$23.00 → $22.00	64%
Truist Securities	Feb 20, 2026	Maintains	Hold	$24.00 → $21.00	67%
Truist Securities	Nov 10, 2025	Maintains	Hold	$17.00 → $24.00	67%
UBS	Nov 5, 2025	Maintains	Neutral	$16.50 → $23.00	64%

The case for and against

Updated Apr 17, 2026

Bull case

Pediatrix Medical Group Inc. demonstrates a positive financial outlook driven by robust reimbursement strength, highlighted by a 4.0% year-over-year increase in same-unit revenue, primarily supported by a 6.7% growth in net reimbursement-related factors. The company benefits from favorable trends in patient acuity and hospital administrative fees, particularly within its neonatology services, which contribute significantly to revenue generation. Additionally, potential upside risks such as improved birth rates, new hospital contracts, and a greater focus on capital deployment further enhance Pediatrix's position in the market.

Bear case

Pediatrix Medical Group's total revenue of $493.8 million in the latest quarter fell slightly short of expectations, indicating potential challenges in sustaining growth, especially with same-unit revenue from patient volume experiencing a decline of 2.7%. Despite improved collections contributing to a decrease in general and administrative expenses, adjusted EBITDA for 2026 and 2027 has not been revised upwards, highlighting concerns about future profitability and margins. The company faces significant downside risks due to sluggish same-unit trends, increasing competition for contracts, declining birth rates, and reimbursement pressures, which collectively undermine its growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.